NO20063676L - Indolderivater og anvendelse derav som kinaseinhibitorer i spesielle IKK2 inhibitorer - Google Patents

Indolderivater og anvendelse derav som kinaseinhibitorer i spesielle IKK2 inhibitorer

Info

Publication number: NO20063676L
Authority: NO; Norway
Prior art keywords: inhibitors; indole derivatives; kinase inhibitors; particular ikk2; kinase
Prior art date: 2004-01-15

Application number

NO20063676A

Other languages

English (en)

Norwegian (no)

Inventor

Paul Bamborough

Lan Robert Baldwin

John Andrew Christopher

Jeffrey K Kerns

Timothy Longstaff

David Drysdale Miller

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-01-15

Filing date

2006-08-15

Publication date

2006-10-13

2006-08-15 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2006-10-13 Publication of NO20063676L publication Critical patent/NO20063676L/no

Links

102100021854 Inhibitor of nuclear factor kappa-B kinase subunit beta Human genes 0.000 title abstract 2
101710205525 Inhibitor of nuclear factor kappa-B kinase subunit beta Proteins 0.000 title abstract 2
239000003112 inhibitor Substances 0.000 title abstract 2
229940054051 antipsychotic indole derivative Drugs 0.000 title 1
150000002475 indoles Chemical class 0.000 title 1
229940043355 kinase inhibitor Drugs 0.000 title 1
239000003757 phosphotransferase inhibitor Substances 0.000 title 1
230000000694 effects Effects 0.000 abstract 2
VFHUJFBEFDVZPJ-UHFFFAOYSA-N 1h-indole-2-carboxamide Chemical class C1=CC=C2NC(C(=O)N)=CC2=C1 VFHUJFBEFDVZPJ-UHFFFAOYSA-N 0.000 abstract 1
108091000080 Phosphotransferase Proteins 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
102000020233 phosphotransferase Human genes 0.000 abstract 1
230000017423 tissue regeneration Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Oncology (AREA)
Neurology (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Virology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Hematology (AREA)

NO20063676A 2004-01-15 2006-08-15 Indolderivater og anvendelse derav som kinaseinhibitorer i spesielle IKK2 inhibitorer NO20063676L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0400895.9A GB0400895D0 (en)	2004-01-15	2004-01-15	Chemical compounds
PCT/GB2005/000085 WO2005067923A1 (en)	2004-01-15	2005-01-13	Indole derivatives and use thereof as kinase inhibitors in particular ikk2 inhibitors

Publications (1)

Publication Number	Publication Date
NO20063676L true NO20063676L (no)	2006-10-13

Family

ID=31726240

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20063676A NO20063676L (no)	2004-01-15	2006-08-15	Indolderivater og anvendelse derav som kinaseinhibitorer i spesielle IKK2 inhibitorer

Country Status (23)

Country	Link
US (1)	US20080269200A1 (de)
EP (1)	EP1703905B1 (de)
JP (2)	JP4975447B2 (de)
KR (1)	KR20070026357A (de)
CN (1)	CN1933830A (de)
AT (1)	ATE413877T1 (de)
AU (1)	AU2005205090A1 (de)
BR (1)	BRPI0506802A (de)
CA (1)	CA2552953A1 (de)
DE (1)	DE602005010970D1 (de)
DK (1)	DK1703905T3 (de)
ES (1)	ES2317184T3 (de)
GB (1)	GB0400895D0 (de)
HR (1)	HRP20090071T3 (de)
IL (1)	IL176739A0 (de)
MA (1)	MA28279A1 (de)
NO (1)	NO20063676L (de)
PL (1)	PL1703905T3 (de)
PT (1)	PT1703905E (de)
RU (1)	RU2006129492A (de)
SI (1)	SI1703905T1 (de)
WO (1)	WO2005067923A1 (de)
ZA (1)	ZA200604855B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR050253A1 (es) *	2004-06-24	2006-10-11	Smithkline Beecham Corp	Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
TW200626142A (en) *	2004-09-21	2006-08-01	Glaxo Group Ltd	Chemical compounds
US8063071B2 (en)	2007-10-31	2011-11-22	GlaxoSmithKline, LLC	Chemical compounds
MX2007016541A (es) *	2005-06-30	2008-03-07	Smithkline Beecham Corp	Compuestos quimicos.
EP1940296A2 (de) *	2005-10-25	2008-07-09	SmithKline Beecham Corporation	Chemische verbindungen
WO2007062318A2 (en) *	2005-11-18	2007-05-31	Smithkline Beecham Corporation	Chemical compounds
WO2007076286A2 (en) *	2005-12-16	2007-07-05	Smithkline Beecham Corporation	Chemical compounds
US8193237B2 (en) *	2007-01-15	2012-06-05	Santen Pharmaceutical Co., Ltd.	Indole derivative having IκB kinase β inhibitory activity
PE20081889A1 (es) *	2007-03-23	2009-03-05	Smithkline Beecham Corp	Indol carboxamidas como inhibidores de ikk2
KR20100115789A (ko)	2008-02-04	2010-10-28	머큐리 테라퓨틱스, 인코포레이티드	Ａｍｐｋ 조절자
US20110009421A1 (en) *	2008-02-27	2011-01-13	Takeda Pharmaceutical Company Limited	Compound having 6-membered aromatic ring
JP2010043070A (ja) *	2008-07-14	2010-02-25	Santen Pharmaceut Co Ltd	カルバモイル基、ウレイド基及び置換オキシ基を有する新規インドール誘導体
EP2404897A4 (de) *	2009-03-05	2014-02-26	Sumitomo Chemical Co	Verfahren zur herstellung von halogensubstituiertem benzendimethanol
WO2010102968A1 (en)	2009-03-10	2010-09-16	Glaxo Group Limited	Indole derivatives as ikk2 inhibitors
US8765792B2 (en)	2010-12-01	2014-07-01	Glaxosmithkline Llc	Indoles
WO2014036268A2 (en) *	2012-08-29	2014-03-06	Mount Sinai School Of Medicine	Indole derivatives as sumo activators
FR3001219A1 (fr) *	2013-01-22	2014-07-25	Centre Nat Rech Scient	Inhibiteurs de kinases
TWI644899B (zh)	2013-02-04	2018-12-21	健生藥品公司	Ｆｌａｐ調節劑
WO2014121055A2 (en) *	2013-02-04	2014-08-07	Janssen Pharmaceutica Nv	Flap modulators
EP3483167A1 (de) *	2013-06-26	2019-05-15	AbbVie Inc.	Primäre carboxamide als btk-hemmer
EP3233835B1 (de) *	2014-12-18	2019-01-23	F.Hoffmann-La Roche Ag	Benzazepinsulfonamidverbindungen
US20170158702A1 (en) *	2015-12-02	2017-06-08	Kyras Therapeutics, Inc.	Multivalent ras binding compounds
US11352328B2 (en)	2016-07-12	2022-06-07	Arisan Therapeutics Inc.	Heterocyclic compounds for the treatment of arenavirus
US11008360B2 (en)	2017-06-07	2021-05-18	Institute Of Chinese Materia Medica, China Academy Of Chinese Medical Sciences	Indoleacetic acid derivative and preparation method and pharmaceutical use thereof
US12419865B2 (en)	2018-12-06	2025-09-23	Arisan Therapeutics Inc.	Compounds for the treatment of arenavirus infection
WO2024059220A2 (en) *	2022-09-15	2024-03-21	Vanderbilt University	6,5 southwestern core compounds as mglu5 negative allosteric modulators and methods of making and using the same

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4775761A (en) *	1983-08-22	1988-10-04	Hoechst-Roussel Pharmaceuticals, Inc.	3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles
DE3342632A1 (de) *	1983-11-25	1985-06-05	Merck Patent Gmbh, 6100 Darmstadt	Indolderivate
US5256673A (en) *	1983-11-25	1993-10-26	Merck Patent Gesellschaft Mit Beschrankter Haftung	Indole-3-yl-A-tetrahydropyridyl or piperidyl compounds
JPH0262875A (ja) *	1988-05-23	1990-03-02	Wakunaga Pharmaceut Co Ltd	新規イソインドリン誘導体
US5254473A (en) *	1990-03-16	1993-10-19	Jp Laboratories	Solid state device for monitoring integral values of time and temperature of storage of perishables
US5330986A (en) *	1992-11-24	1994-07-19	Hoechst-Roussel Pharmaceuticals Inc.	Indole-7-carboxamide derivatives
ZA951822B (en) *	1994-12-23	1996-09-26	Glaxo Group Ltd	Chemical compounds
DE19756036A1 (de) *	1997-12-17	1999-06-24	Merck Patent Gmbh	Amid- und Harnstoffderivate
US6589954B1 (en) *	1998-05-22	2003-07-08	Scios, Inc.	Compounds and methods to treat cardiac failure and other disorders
BR0013122A (pt) *	1999-08-13	2002-04-30	Vela Pharmaceuticals Inc	Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina
US6245799B1 (en) *	1999-11-08	2001-06-12	American Home Products Corp	[(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
AU2001255538B2 (en) *	2000-04-24	2006-03-30	Bristol-Myers Squibb Company	Heterocycles that are inhibitors of IMPDH enzyme
US6897231B2 (en) *	2000-07-31	2005-05-24	Signal Pharmaceuticals, Inc.	Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US20050009876A1 (en) *	2000-07-31	2005-01-13	Bhagwat Shripad S.	Indazole compounds, compositions thereof and methods of treatment therewith
CN1642973A (zh) *	2000-09-06	2005-07-20	奥索-麦克尼尔药品公司	治疗变态反应的方法
US6869956B2 (en) *	2000-10-03	2005-03-22	Bristol-Myers Squibb Company	Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK)
ATE392898T1 (de) *	2000-10-26	2008-05-15	Amgen Inc	Antiphlogistische mittel
PL367305A1 (en) *	2001-06-07	2005-02-21	F.Hoffmann-La Roche Ag	New indole derivatives with 5-ht6 receptor affinity
WO2003024935A2 (en) *	2001-09-19	2003-03-27	Pharmacia Corporation	Substituted pyrazolyl compounds for the treatment of inflammation
AU2002356871A1 (en) *	2001-10-30	2003-05-12	Pharmacia Corporation	Heteroaromatic carboxamide derivatives for the treatment of inflammation
WO2003087087A2 (en) *	2002-04-09	2003-10-23	Astex Technology Limited	Heterocyclic compounds and their use as modulators of p38 map kinase
AR039280A1 (es) *	2002-04-11	2005-02-16	Smithkline Beecham Corp	Compuesto de aminotiofeno y su uso para preparar una composicion farmaceutica
MXPA05005794A (es) *	2002-12-02	2005-08-16	Hoffmann La Roche	Derivados de indazol como antagonistas del factor de liberacion de corticotropina.
WO2004053087A2 (en) *	2002-12-06	2004-06-24	Smithkline Beecham Corporation	Nf-κb inhibitors
WO2005061519A1 (en) *	2003-12-19	2005-07-07	Takeda San Diego, Inc.	Kinase inhibitors
DE102004012069A1 (de) *	2004-03-12	2005-09-29	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue aryl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel
AR050253A1 (es) *	2004-06-24	2006-10-11	Smithkline Beecham Corp	Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
TW200626142A (en) *	2004-09-21	2006-08-01	Glaxo Group Ltd	Chemical compounds
JP5833804B2 (ja) *	2005-04-13	2015-12-16	ニューラクソン，インコーポレーテッド	Ｎｏｓ阻害活性を有する置換インドール化合物
US8063071B2 (en) *	2007-10-31	2011-11-22	GlaxoSmithKline, LLC	Chemical compounds
US7956082B2 (en) *	2005-07-22	2011-06-07	Shionogi & Co., Ltd	Indole derivative having PGD2 receptor antagonist activity
WO2007102883A2 (en) *	2005-10-25	2007-09-13	Smithkline Beecham Corporation	Chemical compounds
EP1940296A2 (de) *	2005-10-25	2008-07-09	SmithKline Beecham Corporation	Chemische verbindungen
WO2007062318A2 (en) *	2005-11-18	2007-05-31	Smithkline Beecham Corporation	Chemical compounds
WO2007076286A2 (en) *	2005-12-16	2007-07-05	Smithkline Beecham Corporation	Chemical compounds
WO2007117465A2 (en) *	2006-03-31	2007-10-18	Abbott Laboratories	Indazole compounds
ATE493411T1 (de) *	2006-09-22	2011-01-15	Glaxo Group Ltd	Pyrroloä2, 3-büpyridin-4-yl- benzolsulfonamidverbindungen als ikk2-hemmer
PE20081889A1 (es) *	2007-03-23	2009-03-05	Smithkline Beecham Corp	Indol carboxamidas como inhibidores de ikk2
GB0710528D0 (en) *	2007-06-01	2007-07-11	Glaxo Group Ltd	Novel compounds

2004
- 2004-01-15 GB GBGB0400895.9A patent/GB0400895D0/en not_active Ceased
2005
- 2005-01-13 AU AU2005205090A patent/AU2005205090A1/en not_active Abandoned
- 2005-01-13 RU RU2006129492/04A patent/RU2006129492A/ru not_active Application Discontinuation
- 2005-01-13 ES ES05701855T patent/ES2317184T3/es not_active Expired - Lifetime
- 2005-01-13 EP EP05701855A patent/EP1703905B1/de not_active Expired - Lifetime
- 2005-01-13 JP JP2006548393A patent/JP4975447B2/ja not_active Expired - Fee Related
- 2005-01-13 CN CNA2005800083624A patent/CN1933830A/zh active Pending
- 2005-01-13 CA CA002552953A patent/CA2552953A1/en not_active Abandoned
- 2005-01-13 PT PT05701855T patent/PT1703905E/pt unknown
- 2005-01-13 SI SI200530567T patent/SI1703905T1/sl unknown
- 2005-01-13 BR BRPI0506802-9A patent/BRPI0506802A/pt not_active IP Right Cessation
- 2005-01-13 KR KR1020067014178A patent/KR20070026357A/ko not_active Withdrawn
- 2005-01-13 PL PL05701855T patent/PL1703905T3/pl unknown
- 2005-01-13 WO PCT/GB2005/000085 patent/WO2005067923A1/en not_active Ceased
- 2005-01-13 US US10/597,154 patent/US20080269200A1/en not_active Abandoned
- 2005-01-13 AT AT05701855T patent/ATE413877T1/de not_active IP Right Cessation
- 2005-01-13 DK DK05701855T patent/DK1703905T3/da active
- 2005-01-13 HR HR20090071T patent/HRP20090071T3/xx unknown
- 2005-01-13 DE DE602005010970T patent/DE602005010970D1/de not_active Expired - Lifetime
2006
- 2006-06-13 ZA ZA200604855A patent/ZA200604855B/xx unknown
- 2006-07-03 MA MA29154A patent/MA28279A1/fr unknown
- 2006-07-06 IL IL176739A patent/IL176739A0/en unknown
- 2006-08-15 NO NO20063676A patent/NO20063676L/no not_active Application Discontinuation
2011
- 2011-09-01 JP JP2011190903A patent/JP2012025761A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
JP2012025761A (ja)	2012-02-09
DE602005010970D1 (de)	2008-12-24
EP1703905B1 (de)	2008-11-12
DK1703905T3 (da)	2009-02-16
US20080269200A1 (en)	2008-10-30
KR20070026357A (ko)	2007-03-08
MA28279A1 (fr)	2006-11-01
BRPI0506802A (pt)	2007-05-29
JP4975447B2 (ja)	2012-07-11
ZA200604855B (en)	2007-11-28
IL176739A0 (en)	2006-10-31
SI1703905T1 (sl)	2009-04-30
GB0400895D0 (en)	2004-02-18
RU2006129492A (ru)	2008-02-27
PL1703905T3 (pl)	2009-04-30
AU2005205090A1 (en)	2005-07-28
WO2005067923A1 (en)	2005-07-28
ATE413877T1 (de)	2008-11-15
HK1098047A1 (en)	2007-07-13
CA2552953A1 (en)	2005-07-28
JP2007517848A (ja)	2007-07-05
PT1703905E (pt)	2009-02-04
CN1933830A (zh)	2007-03-21
EP1703905A1 (de)	2006-09-27
HRP20090071T3 (en)	2009-04-30
ES2317184T3 (es)	2009-04-16

Legal Events

Date	Code	Title	Description
2010-08-23	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
DK1703905T3 (da)	2009-02-16	Indol-derivater og anvendelse deraf som kinaseinhibitorer, især IKK2-inhibitorer
ECSP20027480A (es)	2020-06-30	Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa
NO20071593L (no)	2007-05-22	Pyrimidinderivater
MY151455A (en)	2014-05-30	Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
NO20083427L (no)	2008-10-14	Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20082508L (no)	2008-07-31	Aminopyrimidiner anvendelige som kinaseinhibitorer
NO20064976L (no)	2006-10-31	Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
NO20072567L (no)	2007-07-17	Triazoler nyttige som proteinkinase-inhibitorer
NO20065727L (no)	2006-12-12	Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter
MY147994A (en)	2013-02-28	Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
NO20081893L (no)	2008-05-20	4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft
NO20084435L (no)	2008-11-28	C-MET proteinkinaseinhibitorer
NO20071617L (no)	2007-04-20	Indozolonderivater som 11B-HSD1-inhibitorer
NO20081942L (no)	2008-04-23	Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser
NO20063925L (no)	2006-09-01	Indazolderivater som inhibitorer av hormonsensitiv lipase
NO20076659L (no)	2008-03-18	Pyrrolo(2,3-B)pyridinderivater som protein kinase inhibitorer
NO20070224L (no)	2007-04-02	2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20080141L (no)	2008-01-09	Indanderivater som modulatorer av ionekanaler
UY30500A1 (es)	2008-02-29	Compuestos de azabencimidazolilo
UA99617C2 (ru)	2012-09-10	Производные пирролконденсированного азотсодержащего гетероцикла, их получение и фармацевтическое применение
NO20084489L (no)	2008-12-19	Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
NO20071137L (no)	2007-04-19	Nye piperidinderivater for behandling av depresjon
DK2207770T3 (da)	2011-09-12	1, 2, 3-triazolderivater til anvendelse som stearoyl-coa desaturase-inhibitorer
NO20091590L (no)	2009-05-08	Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer
NI200900052A (es)	2010-02-01	Heterocíclicos derivados de los inhibidores de metaloproteasa